In NSCLC (Non-Small Cell Lung Cancer) cell lines, IGF1R activation could contribute to gefitinib resistance and give rise to the failure of the combination therapy [24, 25]. The gene discussed is IGF1R; the disease is non-small cell lung carcinoma.